vaxxitek® hvt + ibd + nd vaxxitek® hvt + ibd + nd Bursal Disease-Marek's disease-Newcastle disease vaccine, serotype 3, live Marek's disease vector; the vaccine includes a diluent
Collaboration with Mary Tyler Moore Vision Initiative Collaboration with Mary Tyler Moore Vision Initiative Boehringer Ingelheim joins forces with Mary Tyler Moore Vision Initiative to combat vision loss from diabetes
The geography of pet parasites is changing The geography of pet parasites is changing Climate change facilitates new pet parasites way beyond ticks and flea bites in dogs and cats
A life in a day: the reality of living with lung cancer A life in a day: the reality of living with lung cancer Within the initiative “A life in a day”, Anna-Maria spent 24 hours in the shoes of a lung cancer patient to better understand the patient experience.
The Unwearable Collection™ Evolution The Unwearable Collection™ Evolution Get ready for the next stage of The Unwearable Collection™
Boehringer expands production site in Greece Boehringer expands production site in Greece Boehringer expands production site in Greece for new medicine
Boehringer Ingelheim leader in hatchery vaccination Boehringer Ingelheim leader in hatchery vaccination Boehringer Ingelheim is a leader in hatchery vaccination with vector vaccines.
Patient Organizations Patient Organizations Boehringer Ingelheim’s core principles and vision guide our work with patient organisations.
Digital solution for individualized diabetes care Digital solution for individualized diabetes care With Exandra™, we have developed a clinical decision support tool for diabetes care to make everyday life easier for healthcare professionals.
2020 European PRRS Research Award sponsorship 2020 European PRRS Research Award sponsorship 2020 European PRRS Research Award: Boehringer Ingelheim calls for submissions
10 things you should know about rabies 10 things you should know about rabies 10 things you should know about rabies
Partnership Boehringer Ingelheim Lifebit health data Partnership Boehringer Ingelheim Lifebit health data Boehringer Ingelheim and Lifebit announce partnership to capture transformational value of health data
EMA filing acceptance and validation for spesolimab EMA filing acceptance and validation for spesolimab The European Medicines Agency has accepted and validated the marketing authorization application for spesolimab in generalized pustular psoriasis
Generalized pustular psoriasis: Unmet needs Generalized pustular psoriasis: Unmet needs Dr Clerisme-Beaty and Dr Strober MD, PhD discuss the impact of living with GPP including unseen challenges and future management.
European Commission approves SPEVIGO® for new and expanded indications in generalized pustular psoriasis European Commission approves SPEVIGO® for new and expanded indications in generalized pustular psoriasis European Commission approves SPEVIGO® for new and expanded indications in generalized pustular psoriasis
Knowing the enemy: PRRS and PCVD Knowing the enemy: PRRS and PCVD The swine industry is constantly vigilant of viruses such as PRRS and PCV2 (PCVD). Learn about prevention, symptoms knowledge, and control measures to make a difference.
Patient documentary - From diagnosis to everyday living Patient documentary - From diagnosis to everyday living
EASi-KIDNEY™ Phase III trial for people with CKD EASi-KIDNEY™ Phase III trial for people with CKD Boehringer Ingelheim's Sandy Sommer on how treatment innovations in CKD can also improve care for connected conditions, including heart failure.
Blue internal teat sealant now in dairy mastitis portfolio Blue internal teat sealant now in dairy mastitis portfolio Boehringer Ingelheim adds blue internal teat sealant to its dairy mastitis portfolio
Newxxitek™ HVT+ND Newxxitek™ HVT+ND The vaccination of 18 to 19-day-old embryos and one-day-old chickens is effective against Marek’s disease and Newcastle disease.